Date: 2016-08-25
Type of information: Construction of new premises
Compound:
Company: Recipharm (Sweden)
Therapeutic area: Technology - Services
Type agreement: construction of new premises
Action mechanism:
Disease:
Details: * On August 25, 2016, Recipharm, the contract development and manufacturing organisation (CDMO), has announced a €3.7 million investment to expand its lyophilisation capacity in Masate, Italy, in response to growing customer demand. The investment forms part of Recipharm’s strategy to become a leading lyophilisation provider, and is in addition to the ongoing investment at Recipharm in Wasserburg, Germany, where a further €32 million is currently being spent to increase capacity.
Specialising in aseptic manufacturing and filling of parenterals, Recipharm in Masate, located close to Milan, offers lyophilisation capabilities in both vials and ampoules. The investment will see the introduction of a new lyophiliser for vials, bringing the total number of machines from five to six and increasing the facility’s capacity by approximately 20 per cent. The new machine will allow the CDMO to support more drug developers with their stability challenges and meet growing demand for its lyophilisation services, particularly in Europe, China and Japan.
Financial terms:
Latest news:
